Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Diversified Healthcare Trust Q1 2026 Earnings Call - Operational Turnaround Drives Margin Expansion and Deleveraging
Diversified Healthcare Trust delivered a strong first quarter, driven by aggressive operational improvements and strategic asset reallocation. The company’s active management strategy is paying divide...
- Normalized FFO of $0.14 per share and Adjusted EBITDAre of $74 million both beat analyst consensus estimates.
- Same-property SHOP NOI surged 13.5% year-over-year, reaching $44.3 million, driven by 110 basis points of occupancy growth and 5.9% average monthly rate growth.
- Same-property NOI margin expanded by 160 basis points to 14.9%, aided by a 4.5% average annual rate increase across 70% of the portfolio and improved resident mix.
- +7 more takeaways
Playtika Q1 2026 Earnings Call - Disney Solitaire Drives Record Growth and Strategic Shift
Playtika delivered a strong start to 2026, with Q1 revenue rising 9.7% sequentially and 5.5% year-over-year to $744.7 million, driven by exceptional performance from Disney Solitaire and a record Dire...
- Disney Solitaire scaled faster than any title in Playtika’s 15-year history, generating $123.3 million in Q1 revenue, up 72.1% sequentially, with returns supporting heavy user acquisition investment.
- Q1 revenue reached $744.7 million, up 9.7% sequentially and 5.5% year-over-year, beating expectations and supporting raised full-year guidance.
- Direct-to-Consumer (DTC) revenue hit a record $291.8 million, up 16.7% sequentially and 62.8% year-over-year, pushing the annual run rate close to $1.2 billion.
- +9 more takeaways
The Cigna Group Q1 2026 Earnings Call - Raising Full-Year EPS Outlook to $30.35 Amid Strategic Portfolio Shifts
The Cigna Group delivered a strong first quarter 2026, reporting adjusted EPS of $7.79 and raising its full-year outlook to at least $30.35. The results were driven by robust growth in Evernorth's Spe...
- The Cigna Group raised its full-year 2026 adjusted EPS outlook to at least $30.35, up from previous estimates, citing strong Q1 performance and disciplined execution.
- First-quarter adjusted EPS reached $7.79, with total revenues of $68.5 billion, reflecting 16% year-over-year growth.
- Evernorth Specialty and Care Services pre-tax adjusted earnings surged 20% to $1.1 billion, driven by strong specialty volume growth, increased biosimilar adoption, and contributions from the Shields Health Solutions investment.
- +7 more takeaways
Dutch Bros Q1 2026 Earnings Call - Record Q1 Revenue Growth and Raised Full-Year Guidance
Dutch Bros delivered a formidable Q1 2026, with total revenues surging 31% to $464 million and adjusted EBITDA climbing 26%. The company raised its full-year guidance, projecting total revenues of $2....
- Total revenues surged 31% year-over-year to $464 million, significantly outpacing expectations and driving a 26% increase in adjusted EBITDA.
- Full-year guidance was raised across the board, with total revenues now projected at $2.05-$2.08 billion (25%-27% growth) and adjusted EBITDA expected between $370-$380 million.
- System same-shop sales growth hit an exceptional 8.3% in Q1, with transactions up 5.1% for the seventh consecutive quarter of growth.
- +13 more takeaways
TOMI Environmental Solutions Q1 2026 Earnings Call - Carbonium Core Merger and Pipeline Expansion
TOMI Environmental Solutions reported a strong Q1 2026 with revenue up 5% year-over-year and 67% sequentially, driven by a 139% surge in applicator sales and a growing backlog of $2.2 million. The com...
- Revenue reached $1.6 million in Q1 2026, marking a 5% year-over-year increase and a 67% sequential jump from Q4 2025, signaling strong commercial momentum.
- Applicator sales surged 139% year-over-year, surpassing the entire 2025 total in a single quarter, indicating rapid customer adoption of the iHP technology.
- Backlog expanded to $2.2 million from $1.6 million at year-end 2025, reflecting growing demand for automated integrated systems and recurring service contracts.
- +7 more takeaways
Vaxart Q1 2026 Earnings Call - Sentinel Cohort Data Delayed, Revenue Doubles, Runway Extended to Q2 2027
Vaxart reported a strong first quarter with revenue doubling to $39.2 million, driven by BARDA contracts and Dynavax licensing, resulting in a rare net profit of $5.2 million for a clinical-stage biot...
- Revenue doubled to $39.2 million in Q1 2026, up from $20.9 million in Q1 2025, primarily driven by BARDA contract growth and Dynavax licensing revenue.
- Vaxart posted a net income of $5.2 million ($0.02 per share), a rare profitability milestone for a clinical-stage biotech, aided by reduced R&D and G&A expenses.
- Cash and short-term investments stood at $61 million, with the company extending its cash runway into Q2 2027 through cost-cutting and operational streamlining.
- +12 more takeaways
HEI Q1 2026 Earnings Call - Settlement Finalized, Rate Rebasing Requested, and Waiau Project Approved
HEI cleared its most significant overhang by finalizing the Maui wildfire tort settlement and making the first of four $479 million payments. With the litigation resolved, management is pivoting to a ...
- HEI finalized the Maui wildfire tort settlement and made the first $479 million payment in April 2026, removing a major litigation overhang.
- Core net income for Q1 2026 was $31 million, down from $39.8 million in Q1 2025, driven by higher O&M expenses from severe weather and increased insurance costs.
- The PUC approved the Waiau Generating Station repowering project with $908 million in cost recovery through the Exceptional Project Recovery Mechanism (EPRM).
- +7 more takeaways
Nuveen Churchill Direct Lending Corp Q1 2026 Earnings Call - Spreads Widen as Retail Pullback Creates Opportunity in Core Middle Market
Nuveen Churchill Direct Lending Corp (NCDL) reported a resilient first quarter, with net investment income of $0.41 per share and a stable net asset value of $17.50. The slight decline in NAV was driv...
- Net investment income of $0.41 per share, including $0.02 in non-recurring refinancing expenses; excluding those items, income was $0.43 per share.
- Net asset value declined modestly to $17.50 per share from $17.72, primarily due to spread widening and fair value adjustments on underperforming companies.
- Gross originations rose to $83 million in Q1 from $59 million in Q4, with deployment focused on senior secured first lien loans in the core middle market.
- +7 more takeaways
CEMIG Q1 2026 Earnings Call - New CEO Takes Helm as Distribution Growth Offsets Trading Headwinds
CEMIG’s first quarter 2026 results show a utility in transition. Distribution drove the headline numbers with a 26.6% EBITDA jump for Cemig D, fueled by a 7.78% tariff rebasing and solid residential d...
- New CEO Alexandre Ramos Peixoto, a career employee and engineer, replaces Reynaldo Passanezi Filho, who leaves after steering a BRL 70 billion strategic plan and a market value surge from BRL 8 billion to BRL 45 billion.
- CEMIG reported Q1 2026 EBITDA of BRL 1.79 billion and net profit of BRL 979 million, with distribution (Cemig D) leading growth at BRL 1.0 billion EBITDA, up 26.6% year-over-year.
- Cemig D’s rebound is anchored by a 7.78% tariff rebasing in May and rising residential consumption, though distributed generation (DG) now captures 26% of the captive market in Minas Gerais, creating long-term structural headwinds.
- +7 more takeaways
TELUS 2026 Q1 Earnings Call - Sovereign AI Demand and Asset Monetization Drive Free Cash Flow Growth
TELUS delivered a disciplined Q1 2026, posting 1% service revenue growth and 19% year-over-year free cash flow growth of CAD 583 million. The company’s strategic pivot toward high-margin, data-centric...
- TELUS reported 1% year-over-year service revenue growth and stable adjusted EBITDA in Q1 2026, driven by disciplined pricing and premium bundling strategies.
- Free cash flow surged 19% year-over-year to CAD 583 million, supporting a target of CAD 2.45 billion in full-year 2026 and 10% compounded annual FCF growth through 2028.
- TELUS Health delivered 11% adjusted EBITDA growth, generating over CAD 2 billion in annual revenue and targeting CAD 400 million in EBITDA for 2026, with a strategic review underway for potential partnerships.
- +7 more takeaways